Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists
- PMID: 9671109
- DOI: 10.1016/s0014-2999(98)00214-3
Comparison of the in vitro and in vivo profiles of tolterodine with those of subtype-selective muscarinic receptor antagonists
Abstract
Tolterodine [(R)-N,N-diisopropyl-3-(2-hydroxy-5-methylphenyl)-3-phenylpropanamine ] is a new potent and competitive muscarinic receptor antagonist developed for the treatment of urinary urge incontinence and other symptoms of overactive bladder. In vivo, tolterodine exhibits functional selectivity for the urinary bladder over salivary glands, a profile that cannot be explained in terms of selectivity for a single muscarinic receptor subtype. The aim of this study was to compare the in vitro and in vivo antimuscarinic profiles of tolterodine with those of muscarinic receptor antagonists with distinct receptor subtype-selectivity profiles: darifenacin [(S)-2-[1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl]-2,2-d iphenylacetamide; selective for muscarinic M3 receptors]; UH-AH 37 (6-chloro-5,10-dihydro-5-[(1-methyl-4-piperidinyl)acetyl]-11H-dibenzo-[b ,e][1,4]diazepine-11-one; low affinity for muscarinic M2 receptors); and AQ-RA 741 (11-([4-[4-(diethylamino)butyl]-1-piperidinyl]acetyl)-5,11-dihydro-6H-py rido[2,3-b][1,4]benzodiazepine-6-one; high affinity for muscarinic M2 receptors). The in vitro profiles of these compounds were in agreement with previous reports; darifenacin and UH-AH 37 demonstrated selectivity for muscarinic M3/m3 over M2/m2 receptors, while the converse was observed for AQ-RA 741. In vivo, AQ-RA 741 was more potent (1.4-2.7-fold) in inhibiting urinary bladder contraction than salivation in the anaesthetised cat (i.e., a profile similar to that of tolterodine [2.5-3.3-fold]), while darifenacin and UH-AH 37 showed the reverse selectivity profile (0.6-0.8 and 0.4-0.5-fold, respectively). The results confirm that it is possible to separate the antimuscarinic effects on urinary bladder and salivary glands in vivo. The data on UH-AH 37 and darifenacin support the view that a selectivity for muscarinic M3/m3 over M2/m2 receptors may result in a more pronounced effect on salivation than on bladder contraction. The data on AQ-RA 741 may indicate that muscarinic M2/m2 receptors may have a role in bladder contraction.
Similar articles
-
Tolterodine: a review of its use in the treatment of overactive bladder.Drugs Aging. 2001;18(4):277-304. doi: 10.2165/00002512-200118040-00005. Drugs Aging. 2001. PMID: 11341475 Review.
-
Tolterodine--a new bladder-selective antimuscarinic agent.Eur J Pharmacol. 1997 May 30;327(2-3):195-207. doi: 10.1016/s0014-2999(97)89661-6. Eur J Pharmacol. 1997. PMID: 9200560
-
Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine.Pharmacol Toxicol. 1997 Oct;81(4):169-72. doi: 10.1111/j.1600-0773.1997.tb02064.x. Pharmacol Toxicol. 1997. PMID: 9353847
-
Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents.Biol Pharm Bull. 2007 Jan;30(1):54-8. doi: 10.1248/bpb.30.54. Biol Pharm Bull. 2007. PMID: 17202659
-
Tolterodine--a new bladder selective muscarinic receptor antagonist: preclinical pharmacological and clinical data.Life Sci. 1997;60(13-14):1129-36. doi: 10.1016/s0024-3205(97)00057-x. Life Sci. 1997. PMID: 9121357 Review.
Cited by
-
Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.Br J Pharmacol. 2006 Jul;148(5):565-78. doi: 10.1038/sj.bjp.0706780. Epub 2006 Jun 5. Br J Pharmacol. 2006. PMID: 16751797 Free PMC article. Review.
-
Evidence for a M(1) muscarinic receptor on the endothelium of human pulmonary veins.Br J Pharmacol. 2000 May;130(1):73-8. doi: 10.1038/sj.bjp.0703301. Br J Pharmacol. 2000. PMID: 10781000 Free PMC article.
-
Muscarinic receptors in the bladder: from basic research to therapeutics.Br J Pharmacol. 2006 Feb;147 Suppl 2(Suppl 2):S80-7. doi: 10.1038/sj.bjp.0706560. Br J Pharmacol. 2006. PMID: 16465186 Free PMC article. Review.
-
Preserving cognitive function for patients with overactive bladder: evidence for a differential effect with darifenacin.Int J Clin Pract. 2008 Nov;62(11):1792-800. doi: 10.1111/j.1742-1241.2008.01849.x. Epub 2008 Aug 11. Int J Clin Pract. 2008. PMID: 18699842 Free PMC article. Review.
-
Tolterodine: a review of its use in the treatment of overactive bladder.Drugs Aging. 2001;18(4):277-304. doi: 10.2165/00002512-200118040-00005. Drugs Aging. 2001. PMID: 11341475 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous